10-K: Korro Bio Pivots AATD Strategy, Eyes 2026 Clinical Filings

Korro Bio reports significant losses and a strategic shift in its AATD program after a clinical setback, while advancing its hyperammonemia candidate and securing new funding.

Summary

• Korro Bio is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing, targeting both rare and highly prevalent diseases.
• The company incurred a net loss of $117.3 million for the year ended December 31, 2025, compared to $83.6 million in 2024, with an accumulated deficit of $383.8 million.
• A significant non-cash, long-lived asset impairment charge of $30.9 million was recognized in Q4 2025, allocated to operating right-of-use assets ($15.0 million) and property and equipment ($15.9 million).
• The first-generation AATD program, KRRO-110, was terminated in November 2025 after failing to reach projected levels of functional protein in its Phase 1/2a REWRITE clinical trial.
• Korro Bio has pivoted its AATD program to a next-generation GalNAc-conjugated RNA editing oligonucleotide, with a development candidate nomination expected in Q2 2026.
• The lead development candidate, KRRO-121 for hyperammonemia (UCD and HE), is in preclinical development, with a regulatory filing anticipated in the second half of 2026 to enable a first-in-human trial.
• Preclinical data for KRRO-121 demonstrated >90% delivery to the liver in non-human primates, reduced ammonia levels in humanized liver mouse models, and no observed changes in liver or kidney function.
• The collaboration agreement with Novo Nordisk entered a 12-month pause in November 2025, impacting collaboration revenue, which was $6.4 million in 2025 compared to $2.3 million in 2024.
• The company implemented workforce reductions of approximately 20% in May 2025 and an additional 34% in November 2025 to streamline operations and extend cash runway, incurring $3.6 million in restructuring charges in 2025.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $85.2 million, with an expected cash runway into the second half of 2028, supported by recent capital raises.
• The company raised $5.1 million in January 2026 through an at-the-market offering program and $85.0 million in March 2026 through a private placement of common stock and pre-funded warrants.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the significant losses, clinical trial failure, and workforce reductions are clear negatives, the company's decisive pivot in its AATD program and successful capital raises demonstrate resilience and a commitment to advancing its pipeline, albeit in a high-risk, early-stage field.

Positives

• KRRO-121, the lead development candidate for hyperammonemia, shows compelling preclinical data, including >90% liver delivery and ammonia reduction in animal models, with a regulatory filing anticipated in H2 2026.
• The company has secured substantial additional funding, with $5.1 million raised in January 2026 and $85.0 million in March 2026, extending its cash runway into the second half of 2028.
• The strategic pivot for the AATD program to a more potent GalNAc-conjugated delivery system, with >90% editing efficiency in mouse models, indicates a proactive response to clinical setbacks and a commitment to advancing the program.
• Korro Bio's OPERA platform demonstrates versatility in RNA editing applications, including synthetic rescue, repairing pathogenic variants, and activating protein pathways, addressing a broad range of diseases.
• The company's focus on leveraging established delivery modalities like GalNAc-conjugation aims to de-risk lead candidates and improve patient experience through convenient subcutaneous administration.
• The longevity and liver health program targeting AMPK1 activation shows promising preclinical data with improved liver function in obese mice without affecting food intake, suggesting a direct metabolic reprogramming approach.

Negatives

• The company incurred significant net losses of $117.3 million in 2025, an increase from $83.6 million in 2024, and has an accumulated deficit of $383.8 million, indicating continued unprofitability.
• The first-generation AATD program, KRRO-110, failed to reach projected levels of functional protein in its Phase 1/2a REWRITE clinical trial, leading to its termination and a strategic pivot.
• A non-cash, long-lived asset impairment charge of $30.9 million was recognized in Q4 2025, reflecting a reduction in the value of operating right-of-use assets and property and equipment.
• The collaboration agreement with Novo Nordisk, a significant partnership, entered a 12-month pause in November 2025, which will result in no material collaboration revenue during this period.
• The company implemented two workforce reductions in May and November 2025 (totaling approximately 54% of the workforce) to streamline operations and extend cash runway, which can impact morale and future talent acquisition.
• All current programs, including the lead candidate KRRO-121, are still in research or preclinical stages, with high risk of failure and many years before potential commercialization or revenue generation.

Risks

• Incurring significant losses since inception and expecting to incur losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Needing substantial additional funding, and if unable to raise capital when needed, being forced to delay, reduce, eliminate, or prioritize research and development programs or future commercialization efforts.
• Preclinical studies or clinical trials of any lead candidates or development candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or may not produce positive results (as experienced with KRRO-110).
• The gene editing field, particularly RNA editing, is relatively new and evolving rapidly, with limited clinical validation for human therapeutic use, making the approaches unproven and potentially unsuccessful in leading to marketable products.
• Any development candidates may fail in preclinical or clinical development or be delayed to a point where they do not become commercially viable.
• Increased risk that the outcome of clinical trials for oligonucleotides, considered a relatively new class of drugs, will not be sufficient to obtain regulatory approval due to limited regulatory experience and definitive guidelines.
• The business is substantially dependent on the success of KRRO-121, and its failure to advance successfully would materially and adversely affect the company.
• Delays or difficulties in patient enrollment in clinical trials, or other clinical trial delays, could prevent or delay necessary regulatory approvals.
• Inability to successfully manufacture development candidates for research, preclinical, and clinical activities, or insufficient amounts for clinical requirements and timelines, could materially harm the business.
• Development candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, delaying or preventing clinical advancement or regulatory approval.
• Inability to obtain or protect intellectual property rights related to lead candidates and development candidates, or third-party claims of infringement, could adversely affect development and commercialization.
• Unfavorable global economic conditions, including inflation, rising interest rates, and volatile market conditions, and geopolitical events (e.g., U.S. and Israeli military action in Iran), could adversely affect the business.

Future Outlook

Korro Bio anticipates a regulatory filing for KRRO-121 for hyperammonemia in the second half of 2026 to commence a first-in-human trial. A development candidate nomination for the next-generation GalNAc-conjugated AATD program is expected in the second quarter of 2026. The company plans continued advancement of its longevity and liver health and ALS programs, supported by a cash runway into the second half of 2028. There is an expectation to expand the portfolio of RNA editing oligonucleotides to address major unmet medical needs, including highly prevalent diseases.

Management Comments

• We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases.
• We continue to make meaningful advancements across our programs, including KRRO-121 as a potential first-in-class treatment for hyperammonemia that has the potential to address substantial unmet need.
• Following extensive evaluation of our initial AATD program, KRRO-110, we have strategically pivoted from a lipid nanoparticle (LNP) based delivery approach to GalNAc-conjugated delivery and made significant improvements on the potency of the next-generation oligonucleotide.
• We anticipate a regulatory filing to enable commencement of a first-in-human trial in the second half of 2026 for KRRO-121.
• We expect to nominate a development candidate for our AATD program in the second quarter of 2026.
• We believe our existing cash, cash equivalents and marketable securities, together with the net proceeds raised under sales under our at-the-market offering program and March 2026 private placement, will be sufficient to fund our operating expenses and capital expenditure requirements through several value-creating milestones and into the second half of 2028.

Industry Context

StockSavvy.ai notes that Korro Bio operates in the highly competitive and rapidly evolving gene editing and RNA therapeutics space. The company's focus on ADAR-mediated RNA editing represents a novel approach, aiming to overcome limitations of DNA editing by offering transient, titratable, and re-dosable therapies. While the field has seen significant investment and some regulatory approvals for gene therapies and other oligonucleotide modalities (like siRNA and ASOs), RNA editing itself has limited clinical validation. The termination of the KRRO-110 program highlights the inherent risks of novel technology development, but the pivot to GalNAc-conjugated delivery aligns with clinically validated approaches used by competitors like Alnylam (GIVLAARI) and Dicerna (OXLUMO) for liver-targeted oligonucleotide delivery. The pause in the Novo Nordisk collaboration reflects the early-stage and high-risk nature of such partnerships in emerging therapeutic areas. The company's pursuit of indications like hyperammonemia and AATD positions it against both established augmentation therapies and other gene/RNA editing competitors like Beam Therapeutics and Prime Medicine, who are also advancing novel genetic medicine platforms.

Comparison to Industry Standards

• Korro Bio's RNA editing approach aims to differentiate from DNA editing by offering transient and re-dosable therapies, potentially reducing risks of permanent off-target edits seen with CRISPR-Cas9 technologies (e.g., those from Editas Medicine or CRISPR Therapeutics).
• The pivot to GalNAc-conjugated delivery for AATD aligns with successful industry precedents set by companies like Alnylam Pharmaceuticals (GIVLAARI for acute hepatic porphyria) and Dicerna Pharmaceuticals (OXLUMO for primary hyperoxaluria type 1), which have FDA-approved GalNAc-conjugated oligonucleotide therapeutics for liver-targeted delivery.
• The preclinical editing efficiency of >90% for the next-generation AATD candidate in mouse models is a strong indicator, comparable to the high efficacy targets often sought in oligonucleotide therapies.
• The failure of KRRO-110 (LNP-based) to reach projected protein levels in a Phase 1/2a trial highlights the challenges of novel delivery systems, contrasting with the more established LNP success seen in mRNA vaccines (e.g., Pfizer-BioNTech, Moderna) or some siRNA therapies.
• The company's cash runway into H2 2028, following recent capital raises, provides a competitive timeframe for advancing preclinical programs to clinical stages, similar to many early-to-mid-stage biotech companies in the high-burn R&D phase.
• The pause in the Novo Nordisk collaboration, while a setback, is not uncommon in early-stage biotech partnerships where programs are re-evaluated based on emerging data or strategic shifts, as seen in various collaborations across the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings as of December 31, 2025.

Related Party Transactions

• The filing incorporates by reference information on certain relationships and related transactions from the definitive proxy statement for the 2026 annual meeting of stockholders, but no specific related party dealings are detailed in the main body of the 10-K.

Stakeholder Impact

• **Shareholders**: Face increased risk due to significant losses, early-stage pipeline, and the failure of a lead clinical program (KRRO-110). However, recent capital raises and strategic pivots aim to extend runway and improve future prospects. Stock price volatility is a noted risk.
• **Employees**: Affected by two rounds of workforce reductions (approximately 54% total), leading to potential morale issues and challenges in future talent acquisition. Remaining employees face increased demands.
• **Patients (UCD/HE)**: Potential for a new first-in-class treatment (KRRO-121) in preclinical development offers hope for improved ammonia control and dietary liberalization, addressing significant unmet needs.
• **Patients (AATD)**: The termination of KRRO-110 is a setback, but the strategic pivot to a next-generation GalNAc-conjugated therapy offers a renewed, potentially more effective, approach to disease modification.
• **Collaborators (Novo Nordisk)**: The 12-month pause in the collaboration impacts the progress of partnered programs and revenue streams for Korro Bio, reflecting a re-evaluation of the partnership's immediate future.
• **Creditors**: The company's ability to raise additional capital and extend its cash runway into H2 2028 provides some stability, but recurring losses and the early stage of development present ongoing financial risk.

Next Steps

• Regulatory filing for KRRO-121 for hyperammonemia anticipated in the second half of 2026 to enable commencement of a first-in-human trial.
• Nomination of a development candidate for the next-generation GalNAc-conjugated AATD program expected in the second quarter of 2026.
• Continued design and screening of additional oligonucleotides to optimize editing efficiency and drug-like properties for the AATD GalNAc program.
• Continued advancement of the longevity and liver health program targeting AMPK1 activation, including identifying and characterizing MASH and liver fibrosis models.
• Continued advancement of the ALS program targeting TDP-43, including designing and screening additional oligonucleotides and identifying ALS cell lines.
• GLP-compliant toxicology studies in mouse and monkey are planned to support the proposed first-in-human study for KRRO-121.
• Remaining payments related to the November 2025 workforce reduction are expected to be paid by the third quarter of 2026.
• The company will continue to evaluate and update its cybersecurity policies and procedures to align with its risk profile.

Key Dates

Recommendation

Korro Bio presents a high-risk, high-reward profile. The termination of the KRRO-110 clinical program and the pause in the Novo Nordisk collaboration are significant setbacks, contributing to substantial losses and an impairment charge. However, the company has demonstrated resilience by securing new capital, extending its cash runway, and strategically pivoting its AATD program with promising preclinical data for a new candidate. The lead candidate, KRRO-121, also shows strong preclinical results and is moving towards clinical trials. Given the early stage of all programs and the inherent uncertainties of novel RNA editing technology, a 'hold' recommendation is appropriate. Investors should monitor the progress of KRRO-121's regulatory filing and first-in-human trial, as well as the nomination of the next-generation AATD candidate, for clearer indicators of future success. The recent capital raise provides a buffer, but the path to profitability remains long and uncertain.

Keywords

RNA editing, genetic medicines, biopharmaceutical, hyperammonemia, UCD, hepatic encephalopathy, AATD, alpha-1 antitrypsin deficiency, GalNAc-conjugated, oligonucleotide, OPERA platform, preclinical development, clinical trials, biotech, drug development, gene editing, ADAR, KRRO-121, AMPK1, ALS, TDP-43, Novo Nordisk